MiMedx Challenges FDA Classification Of Wound Care Powder

By Kelcey Caulder · March 20, 2025, 8:02 PM EDT

Biomedical company MiMedx Group urged a Georgia federal judge on Thursday to overturn the U.S. Food and Drug Administration's classification of a wound care treatment as a biological product, arguing the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

MiMedx Group, Inc. v. U.S. Food and Drug Administration et al

Case Number

1:24-cv-01287

Court

Georgia Northern

Nature of Suit

Other Statutes: Administrative Procedures Act/Review or Appeal of Agency Decision

Date Filed

March 25, 2024

Recent Articles By Kelcey

March 27, 2025
EMS Co. Accused Of Failing To Pay Proper Overtime
March 14, 2025
Ga. Panel Says COVID-Era Legal Shield Blocks Amputee's Suit
February 11, 2025
Feds Seek $55K In Restitution In VA Doc Sex Abuse Case
February 07, 2025
Ga. Hospital Should Face Insurer's Suit Over Double-Billing
January 15, 2025
Justices Asked If Zoning Immunity Can Pass To Private Entity
January 06, 2025
Ga. Physician Assistant Sues Insurer Over Disability Benefits
December 16, 2024
11th Circ. Appears Wary Of Doc's New Trial Bid In $27.5M Case
December 11, 2024
Ga. Judge Refuses To Reconsider Toss Of Patient Data Suit
December 06, 2024
AngioDynamics Port Defect Caused Infection, Ga. Man Says
December 05, 2024
Atlanta VA Surgeon Botched Routine Hysterectomy, Suit Says